{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE310nnn/GSE310042/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310042"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Comprehensive transcriptome and epigenome profiling of A2780 models reveals distinct programs of cisplatin, paclitaxel, and dual resistance [RNA-seq]","description":"Ovarian cancer is the most lethal gynecologic cancer, largely because most patients eventually relapse after initially responding to platinum- and taxane-based chemotherapy. To understand how cancer cells adapt to these drugs, we generated cisplatin-resistant (CpR), paclitaxel-resistant (TxR), and dual-resistant (TxCpR) derivatives from the parental A2780 cell line and profiled their transcriptomes and chromatin landscapes using RNA-seq and ATAC-seq. The three resistant lines displayed distinct cellular morphologies, gene expression profiles, and chromatin accessibility patterns. Notably, the dual-resistant state was not simply a combination of the cisplatin- and paclitaxel-resistant states but instead represented a unique regulatory configuration. Integrative analysis of RNA-seq and ATAC-seq identified potential regulators associated with specific drug-resistance of A2780. Furthermore, we suggested resistance-specific distal regulatory regions highly related with transcription factors either directly or indirectly involved in cancer progression, cell plasticity and chemotherapy resistance. Our paired RNA-seq and ATAC-seq datasets provide valuable and comprehensive resources for exploring how enhancer–transcription factor interactions drive chemotherapy resistance and for identifying new therapeutic targets in ovarian cancer.","dates":{"publication":"2026/08/10"},"accession":"GSE310042","cross_references":{"GSM":["GSM9287091","GSM9287090","GSM9287097","GSM9287096","GSM9287093","GSM9287092","GSM9287095","GSM9287094"],"GPL":["34284"],"GSE":["310042"],"taxon":["Homo sapiens"]}}